secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0000950170-25-105839
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen Q2 2025 net income $39.7M on non-cash gains; cash $90.4M, appoints new clinical VP
--------------------------------------------------------------------------------

- Net income of $39.7M ($2.55/diluted share) versus net loss of $25.3M in Q2 2024; driven by non-cash gains on tranche liability and warrant revaluation.
- Cash and cash equivalents $90.4M at June 30, 2025, down from $101.6M at March 31, 2025.
- Appointed Daniel Chao, M.D., Ph.D., as VP and Head of Clinical Development; also formed Clinical Advisory Board with four retinal specialists.
- Granted U.S. Patent No. 12,297,278 covering SWAP multi-specific Wnt surrogate technology; IND submission for SZN-8141 targeted for 2026.
- R&D expenses $6.0M (up from $5.3M) and G&A $4.0M (up from $3.7M); research service revenue from related party $1.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017025105839/0000950170-25-105839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017025105839/srzn-20250808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer